Publish in this journal
Journal Information
Vol. 73. Issue 3.
Pages 219-224 (March 2020)
Not available
Vol. 73. Issue 3.
Pages 219-224 (March 2020)
Original article
Full text access
Transcatheter closure of patent foramen ovale in patients older than 60 years of age with cryptogenic embolism
Cierre percutáneo del foramen oval permeable en pacientes mayores de 60 años con ictus criptogénico
Jérôme Wintzer-Wehekinda, Alberto Alperia, Christine Houdeb, Jean-Marc Côtéb, David del Vala, Mélanie Côtéa, Josep Rodés-Cabaua,b,
Corresponding author

Corresponding author: Quebec Heart & Lung Institute, Laval University, 2725 Chemin Ste-Foy, G1V 4GS, Quebec City, Quebec, Canada.
a Quebec Heart and Lung Institute, Laval University, Quebec, Canada
b Centre Hospitalier Universitaire de Quebec, Quebec, Canada
Related content
Jaime Masjuan, Sebastián García-Madrona, Alicia de Felipe
This item has received
Article information
Full Text
Download PDF
Figures (2)
Tables (3)
Table 1. Baseline clinical characteristics according to age (> 60 years vs ≤ 60 years)
Table 2. Procedural characteristics and in-hospital outcomes according to patients’ age
Table 3. Long-term clinical outcomes following patent foramen ovale closure, according to patients’ age
Show moreShow less
Introduction and objectives

Randomized trials have shown the efficacy of transcatheter closure of patent foramen ovale (PFO) in patients aged ≤ 60 years with cryptogenic embolism. We aimed to assess the long-term safety and efficacy of PFO closure in patients aged> 60 years.


Of 475 consecutive patients with cryptogenic embolism who underwent PFO closure, 90 older patients aged> 60 years (mean, 66±5 years) were compared with 385 younger patients aged ≤ 60 years (mean, 44±10 years).


Older patients had a higher prevalence of cardiovascular risk factors (CVRF) (hypertension, dyslipidemia, diabetes; P <.01 for all vs younger patients). There were no differences in periprocedural complications between the 2 groups. During a median follow-up of 8 (4-12) years, there were a total of 17 deaths, all from noncardiovascular causes (7.8% and 2.6% in the older and younger patient groups, respectively; HR, 4.12; 95%CI, 1.56-10.89). Four patients had a recurrent stroke (2.2% and 0.5% in the older and younger patient groups, respectively; HR, 5.08; 95%CI, 0.71-36.2), and 12 patients had a transient ischemic attack (TIA) (3.3% and 2.3% in the older and younger patient groups, respectively; HR, 1.71; 95%CI, 0.46-6.39). There was a trend toward a higher rate of the composite of stroke/TIA in older patients (5.5% vs 2.6%; HR, 2.62; 95%CI, 0.89-7.75; P=.081), which did not persist after adjustment for CVRF (HR, 1.97; 95%CI, 0.59-6.56; P=.269).


In older patients with cryptogenic embolism, PFO closure was safe and associated with a low rate of ischemic events at long-term. However, older patients exhibited a tendency toward a higher incidence of recurrent stroke/TIA compared with younger patients, likely related to a higher burden of CVRF.

Patent foramen ovale
Transient ischemic attack
Introducción y objetivos

Estudios aleatorizados han mostrado la eficacia del cierre percutáneo del foramen oval permeable (FOP) en pacientes de edad ≤ 60 años con ictus criptogénico. El objetivo de este estudio es determinar la seguridad y la eficacia a largo plazo del cierre percutáneo del FOP en pacientes mayores de 60 años con ictus criptogénico.


De 475 pacientes consecutivos con ictus criptogénico que se sometieron al cierre del FOP, 90 eran mayores de 60 años (media, 66±5 años) y se los comparó con los 385 del grupo de edad ≤ 60 años (media, 44±10 años).


Los pacientes mayores de 60 años tuvieron mayor prevalencia de factores de riesgo cardiovascular (FRCV) (hipertensión, dislipemia y diabetes; p <0,01). No hubo diferencias en cuanto a complicaciones periprocedimiento. El seguimiento medio fue de 8 (4-12) años y hubo 17 muertes, todas de causa no cardiovascular (el 7,8% de los mayores de 60 años y el 2,6% de los de edad ≤ 60 años; HR=4,12; IC95%, 1,56-10,89). Tuvieron un ictus recurrente 4 pacientes (el 2,2% de los mayores de 60 años frente al 0,5% de los de edad ≤ 60 años; HR=5,08; IC95%, 0,71-36,2), y un accidente isquémico transitorio (AIT) 12 pacientes (el 3,3 frente al 2,3%; HR=1,71; IC95%, 0,46-6,39). Hubo tendencia a una mayor incidencia de ictus/AIT en los mayores de 60 años (el 5,5 frente al 2,6%; HR=2,62; IC95%, 0,89-7,75; p=0,081), que no persistió tras ajustar por FRCV (HR=1,97; IC95%, 0,59-6,56; p=0,269).


El cierre percutáneo del FOP en pacientes mayores de 60 años con ictus criptogénico resultó seguro y se asoció con una baja incidencia de eventos isquémicos a largo plazo. Sin embargo, en los pacientes mayores de 60 años se observó una tendencia a mayor incidencia de ictus/AIT probablemente relacionada con mayor prevalencia de FRCV.

Palabras clave:
Foramen oval permeable
Accidente isquémico transitorio
Edad avanzada
Full Text

In patients with cryptogenic stroke, up to 4 randomized trials and subsequent meta-analyses have recently shown a significant reduction in recurrent ischemic stroke events following percutaneous closure of patent foramen ovale (PFO).1–6 All randomized trials but one excluded patients older than 60 years, and a mean patient age of about 50 years was reported in the single randomized trial including older patients.3 Thus, whereas PFO closure has been established as the new gold-standard therapy in young patients with cryptogenic stroke and PFO, there are no definite recommendations on the management of patients older than 60 years.7–9 Some studies have shown that older patients with cryptogenic stroke exhibit a much higher prevalence of PFO (compared with patients with stroke of known cause), similar to that in younger populations,10,11 but scarce data exist on acute and mid-term clinical outcomes of older patients undergoing PFO closure.12–16 In addition, no studies to date have specifically focused on the long-term outcomes of patients older than 60 years.

The objective of our study was to evaluate long-term clinical outcomes following transcatheter PFO closure in older (> 60 years) patients with cryptogenic embolism.


A total of 475 consecutive patients who underwent PFO closure between 2001 and 2018 because of cryptogenic embolism (stroke, transient ischemic attack [TIA], peripheral embolism) were included. A presumptive diagnostic of paradoxical embolism was established by a neurologist after screening including brain magnetic resonance imaging and/or brain computed tomography, 24-hour Holter monitoring, transthoracic echocardiography (TTE), transesophageal echocardiography (TEE), and transcarotid Doppler. The diagnosis of PFO was established on the basis of a right to left shunt during TEE examination with agitated saline contrast test with and without Valsalva maneuver. The shunt was classified as small, moderate or large, with or without atrial septal aneurysm.17

The type and size of the implanted device were left to the criteria of the physician performing the procedure. Postprocedural TTE was performed in all patients prior to hospital discharge, typically a few hours after the procedure to confirm device position, evaluate residual shunt, and exclude pericardial effusion. Medical therapy at discharge was (usually) aspirin (indefinitely), and clopidogrel was added in some patients (for 6 months) according to the preference of the physician performing the procedure. Anticoagulation was prescribed in the presence of other medical reasons requiring anticoagulation therapy (pulmonary embolism, deep venous thrombosis). At 1- to 6-months postprocedure, patients had a clinical visit and an echocardiographic (TTE and/or TEE) examination. All procedural and 1- to 6-month follow-up data were prospectively entered into a dedicated database.

Follow-up was ensured by the referral neurologist/cardiologist or the physician performing the PFO closure along with the family physician responsible for the patient, but there was no pre-established timing for the clinical visits during the follow-up period after the 1-year follow-up. The medical records of all patients were reviewed and data on all clinical events and current medications were collected. In addition, a systematic clinical visit or telephone call was conducted in all patients with no follow-up data. Each patient was asked about recurrences of stroke, TIA or peripheral embolism, new hospitalizations (and reason), bleeding, arrhythmias and cardiac events, migraine, and current medications. When an event was suspected on the basis of the questionnaire, the complete medical file of the center taking care of the patient was consulted. The patient's primary care physician and cardiologist/neurologist responsible for the patient were consulted if any further information was needed.

All neurological events (stroke, TIA) were diagnosed by a neurologist and defined according to TOAST criteria.18 All bleeding events were recorded and classified according to the BARC criteria.19

Statistical analysis

Categorical variables are reported as No. (%). Continuous variables are expressed as mean±standard deviation or median (25th to 75th interquartile range) depending on variable distribution. Group comparisons were analyzed using the Student t test or Wilcoxon rank sum test for continuous variables, and chi-square test of Fisher exact test for categorical variables. A propensity score analysis was performed to adjust intergroup (≤ 60 year-old group vs> 60 year-old group group) differences in baseline characteristics. The selected variables were body mass index, smoking, hypertension, dyslipidemia, diabetes, pulmonary embolism and antithrombotic treatment, using a logistic regression analysis. Clinical outcomes were compared between groups with the use of proportional hazard models. Further comparisons were performed with the Tukey technique. Clinical event rates were also summarized by using the Kaplan-Meier estimates, and comparisons between groups were performed with the log-rank test. Results were considered significant at the <.05 level. All analyses were conducted using the statistical package SAS version 9.4 (SAS Institute Inc, Cary, North Carolina, United States).

RESULTSBaseline characteristics

Of 475 patients who underwent PFO closure, 90 patients (18.9%) were older than 60 years at the time of the closure (mean age of 66±5 years, vs 44±10 years in the group aged ≤ 60 years). The baseline characteristics of the patients according to age at the time of PFO closure are shown in table 1.

Table 1.

Baseline clinical characteristics according to age (> 60 years vs ≤ 60 years)

  > 60 years(n=90)  ≤ 60 years(n=385)  P 
Age, y  66±44±10  <.001 
Female sex  46 (51.1)  183 (47.5)  .559 
Body mass index, kg/m2  28.4±5.8  26.9±5.6  .023 
Current smoking  5 (5.6)  46 (11.9)  .089 
Hypertension  44 (48.9)  59 (15.3)  <.001 
Dyslipidemia  33 (36.7)  61 (15.8)  <.001 
Diabetes mellitus  9 (10.0)  11 (2.9)  .006 
Migraine antecedents  9 (10.0)  79 (20.5)  .023 
Oral contraception  0 (0)  20 (5.2)  .019 
Pulmonary embolism  6 (6.7)  10 (2.6)  .095 
Deep vein thrombosis  9 (10.0)  28 (7.3)  .385 
Closure indication
Stroke  69 (76.7)  286 (74.3)  .688 
TIA  29 (32.2)  116 (30.1)  .704 
Peripheral embolism  4 (4.4)  8 (2.1)  .254 
Shunt preprocedure      .334 
Mild  17 (18.9)  92 (23.9)   
Moderate/severe  73 (81.1)  293 (76.1)   
Atrial septal aneurysm  37 (41.1)  124 (32.2)  .176 
RoPE score  4.6±1.1  7.2±1.4  <.001 

RoPE, risk of paradoxical embolism; TIA, transient ischemic attack.

Values are reported as No. (%) or mean±standard deviation.

There were no statistically significant differences between groups in terms of sex, venous thromboembolic disease, current smoking, closure indication, baseline PFO shunt severity, or the presence of atrial septal aneurysm. However, the older group was more likely to have cardiovascular risk factors such as hypertension, dyslipidemia, diabetes, and a higher body mass index. Older patients had also a higher risk of paradoxical embolism (RoPE) score.

Procedural results

There were no statistically significant differences between groups regarding procedural and in-hospital outcomes (table 2). Device implantation was successful in all cases and a similar (low) rate of residual shunt at discharge was observed in both groups. The Amplatzer PFO device (Abbott, Chicago, IL, United States) was used in the vast majority of patients in both groups. Only one episode of atrial fibrillation (AF) post closure occurred in a patient who experienced an esophageal hematoma secondary to the TEE probe in the younger group and who made a full recovery after simple observation. There was a trend toward a bigger device size in the older group.

Table 2.

Procedural characteristics and in-hospital outcomes according to patients’ age

  Age> 60 years (n=90)  Age ≤ 60 years (n=385)  P 
Successful device implantation  90 (100)  385 (100)  — 
Device type      .163 
Amplatzer PFO  82 (91.1)a  320 (83.1)  — 
Amplatzer ASD  4 (4.4)  46 (11.9)  — 
Amplatzer cribiform  1 (0.2)  2 (0.5)  — 
Premere  3 (3.3)  16 (4.1)  — 
Cardia  0 (0)  1 (0.2)  — 
Device size, mm      .056 
<25  6 (6.7)  39 (10.1)  — 
25  61 (67.8)  288 (74.8)  — 
> 25  23 (25.6)  58 (15.1)  — 
In-hospital complications
Device embolization  0 (0)  0 (0)  — 
Device thrombosis  0 (0)  0 (0)  — 
Atrial fibrillation  0 (0)  1 (0.3)  1.00 
Tamponade  0 (0)  0 (0)  — 
Esophageal hematoma  0 (0)  1 (0.3)  1.00 
Deep venous thrombosis  0 (0)  1 (0.3)  1.00 
Pulmonary embolism  0 (0)  1 (0.3)  1.00 
Major vascular complication  1 (1.1)  0 (0)  .189 
Residual shunt at discharge  13 (14.4)  42 (10.9)  .362 
Mild  13 (14.4)  41 (10.6)  1.00 
Moderate  0 (0)  1 (0.2)  1.00 
Antithrombotic treatment at hospital discharge
Aspirin  62 (68.9)  345 (89.6)  <.001 
Clopidogrelb  27 (30)  61 (15.8)  .004 
Anticoagulation  12 (13.3)  22 (5.7)  .021 

Values are reported as No. (%) or mean±standard deviation.


One patient in the> 60 year group needed 2 devices (25 and 30mm).


Including 5 (5.5%) and 38 (9.9%) patients with concomitant aspirin and clopidogrel therapy in the groups aged> 60 years and ≤ 60 years, respectively.

Regarding antithrombotic therapy at hospital discharge, aspirin was more often prescribed in younger patients, whereas clopidogrel and oral anticoagulation was more frequently prescribed in older participants. Because no patient had AF during the evaluation process, a higher rate of previous pulmonary embolism and peripheral venous thrombosis in the older group (despite nonsignificant differences between groups) may have led to a higher rate of anticoagulation at discharge. After PFO closure, antithrombotic treatment was left to the discretion of the referral neurologist or cardiologist. Finally, there were no reasons other than PFO closure to prescribe dual antiplatelet therapy in some patients.


The median follow-up of the entire study population was 8 (4-12) years. Follow-up was complete in all patients except 21 (4.4%, lost to follow-up; 19 [4.9%] and 2 [2.2%] patients in the younger and older patient groups, respectively), leading to a total of 366 and 88 patients with complete follow-up in the younger and older patient groups, respectively. The main clinical outcomes according to patient age (≤ 60 vs> 60 years) are shown in table 3. All-cause mortality was higher in the older group (hazard ratio [HR], 4.12, 95% confidence interval [95%CI], 1.56-10.89; P=.004), and differences persisted after adjustment (HR, 4.58, 95%CI, 1.61-13.1; P=.005). Of the 17 deaths, all were of noncardiovascular origin (cancer in 7, severe dementia in 1, car accident in 1, chronic pulmonary embolism hypertension in 1, intracerebral hemorrhage due to cerebral aneurysm in 1, suicide in 3, unknown origin in 3). A total of 4 patients experienced recurrent stroke events (0.8%) during the follow-up period, with no significant differences between groups (2.2% and 0.5% in the older and younger patient groups, respectively; HR, 5.08; 95%CI, 0.71-36.2; P=.105). All strokes were considered as non-PFO mediated (1 stroke 5 years post-PFO closure was considered as atherothrombotic in a patient with up to 4 cardiovascular risk factors; another patient had a stroke due to vertebral dissection; 1 stroke was related to a bioprosthetic aortic valve thrombosis; 1 patient had recurrent strokes without clear etiology). TIA events occurred in 12 patients (2.5%), with no differences between groups (3.3% vs 2.3% in the older and younger patient groups, respectively; HR, 1.71; 95%CI; 0.46-6.39; P=.424). In the univariate analysis, the combined endpoint of stroke or TIA tended to be higher in the older patient group (5.5% vs 2.6%; HR, 2.62; 95%CI, 0.89-7.75; P=.081), but this trend did not remain after adjustment (HR, 1.97; 95%CI, 0.59-6.56; P=.269). AF and myocardial infarction events were more likely to occur in the older group, but differences did not persist after adjustment. The Kaplan-Meier curves for the main clinical events after adjustment up to 12-year follow-up are shown in figure 1.

Table 3.

Long-term clinical outcomes following patent foramen ovale closure, according to patients’ age

  > 60 years(n=90)  ≤ 60 years(n=385)  HR (95%CI)  P  Adjusted HR  P 
Death  7 (7.8)  10 (2.6)  4.12 (1.56-10.89)  0.004  4.58 (1.61-13.1)  .005 
Stroke  2 (2.2)  2 (0.5)  5.08 (0.71-36.2)  0.105  1.36 (0.14-13.4)  .791 
TIA  3 (3.3)  9 (2.3)  1.71 (0.46-6.39)  0.424  1.65 (0.40-6.91)  .495 
Composite of stroke and TIA  5 (5.5)  10 (2.6)  2.62 (0.89-7.75)  0.081  1.97 (0.59-6.56)  .269 
DVT/pulmonary embolism  2 (2.2)  6 (1.5)  1.88 (0.37-9.39)  0.444  1.26 (0.20-8.11)  .801 
Atrial fibrillation  5 (5.5)  7 (1.8)  4.09 (1.28-13.16)  0.018  2.26 (0.60-8.50)  .225 
Myocardial infarction  3 (3.3)  3 (0.8)  5.34 (1.08-26.5)  0.04  3.27 (0.55-19.7)  .195 

95%CI, 95% confidence interval; DVT, deep vein thrombosis; HR, hazard ratio; TIA, transient ischemic attack.

Values are reported as No. (%).

Figure 1.

Kaplan-Meier estimates for clinical events at 12-year follow-up after adjusting for differences in baseline characteristics between groups. Kaplan-Meier plots showing: cumulative mortality (A), stroke (B), TIA (C), and stroke and TIA (D) at a 12-year follow-up according to age (≤ 60 years or > 60 years). 95%CI, 95% confidence interval; HR, hazard ratio; TIA, transient ischemic attack.


To put these results into perspective, the stroke/TIA event rate in our study population was compared with that expected according to the RoPE score20 (figure 2). According to this score, the rate of stroke/TIA at the 2-year follow-up would have been of 6.2% and 10.6% under medical therapy only, vs the observed rate of 1.2% and 5.5% in younger and older PFO closure groups, respectively (P=.001 for both).

Figure 2.

Comparisons between expected events estimated by RoPE (risk of paradoxical embolism) score and observed events according to age (≤ 60 years or> 60 years). TIA, transient ischemic attack.


The main results of our study can be summarized as follows: a) older patients with cryptogenic embolism and PFO exhibited a higher burden of cardiovascular risk factors; b) PFO closure was safe in older patients, with no differences in periprocedural complications compared with younger patients; c) at long-term (median of 8 years) follow-up post-PFO closure, the global mortality rate was higher among older patients, but differences were driven by noncardiovascular mortality (mainly cancer), and d) the rate of recurrent stroke/TIA was low (much lower than that predicted by the RoPE score), but there was a tendency toward a higher incidence of recurrent stroke/TIA among older patients, which appeared to be partially related to cardiovascular risk factor burden (no differences in recurrent ischemic event rate were observed after adjustment for baseline differences in cardiovascular risk factors between groups).

Several studies have shown that transcatheter PFO closure is a safe procedure in young (< 60 years) patients. However, scarce and controversial data exist on periprocedural complications in older patients. Merkler et al.21 showed a higher risk of in-hospital complications among older patients undergoing PFO closure, with a periprocedural complication rate double that observed in patients aged <60 years. In contrast, similar to the results of our study, Wahl et al.15 showed the absence of an increased periprocedural risk in older patients undergoing PFO closure. These data are reassuring and important, particularly considering the lack of randomized data and specific guideline recommendations on PFO closure in older patients.7,8

Our study is the first to provide long-term data following PFO closure in patients older than 60 years. A mean difference in age of approximately 20 years was observed between younger (< 60 years) and older patients and, not surprisingly, the long-term mortality rate among older patients was much higher than that observed in the younger population. Of note, all deaths following PFO closure were of noncardiovascular origin (with cancer as the most frequent cause of death), and the death rate observed in older patients was similar to that reported by the Institut de la Statistique du Québec for the Quebec Canadian population of the same age and sex (6.6% probability of death in the 5 years following the 65th birthday in men and 4.4% for women).22 Thus, the mortality difference observed between younger and older patients in this study seems to be driven by the higher risk of dying in older people.

The rate of recurrent thromboembolic events at long-term follow-up post-PFO closure in older patients was low, with only 2 strokes and 3 TIA episodes occurring during the follow-up period. This represents a rate of 0.3 strokes per 100 person-years and 0.8 stroke/TIA per 100 person-years, which is much lower than the incidence estimated by the RoPE score, suggesting that the beneficial effects of PFO closure may extend beyond the limit of 60 years. Previous studies have shown a low incidence of ischemic events at 1 to 3 years following PFO closure in older patients13–15 and the results of our study extend these positive findings to the long-term (> 5 years) follow-up of these patients. However, we observed a tendency toward a higher incidence of cerebrovascular events (stroke/TIA) in older (vs younger) patients. The fact that this tendency disappeared after adjustment for cardiovascular risk factors suggests a potential role of atherosclerotic burden in some of the ischemic events observed in older patients.

It is well-known that the prevalence of cardiovascular risk factors (particularly hypertension and diabetes) steadily increases with age, and the prevalence observed in our population of older patients is similar to that reported in the Canadian population of the same age range.23 However, the prevalence of risk factors such as dyslipidemia (35.6%), hypertension (48.9%) or diabetes (10%) was much higher than that observed in younger patients. In addition, Alsheikh-Ali et al.24 reported that in patients with cryptogenic stroke, 20% (16% to 25%) and 48% (34% to 66%) of PFOs are likely to be incidental in younger and older patients, respectively. Interestingly, these rates decrease to 9% (4% to 18%) in younger patients and to 26% (12% to 56%) in older patients when a concomitant atrial septal aneurysm is detected. This highlights the need for careful patient evaluation by an interdisciplinary team including neurologists, cardiologists, and the patient's own point of view, as described in recent guidelines.7,8 In addition, a higher incidence of AF episodes was observed among older patients in the years following PFO closure, further stressing the importance of AF screening in these patients before PFO closure. Moreover, these data raise the question about the use of longer term cardiac monitoring or even consideration of insertable cardiac monitors in some of these patients.25

The limitations of this study include those inherent to retrospective studies. Although the number of patients lost to follow-up was very low (particularly considering the long-term follow-up), we cannot completely exclude the possibility of missing some adverse events. However, this would be highly unlikely with regard to major events and those requiring rehospitalization. Also, medical records were reviewed to obtain data on patient hospitalizations over time. Finally, the referral cardiologist/neurologist, family physicians and pharmacists were also contacted if there were doubts regarding events and/or medication. The echo data were site reported and not analyzed in a central echocardiographic laboratory.


This study shows that PFO closure in patients older than 60 years is safe and associated with a low event rate at long-term follow-up. These results emphasize the need for the design of future randomized trials involving older patients with PFO and cryptogenic embolism. Meanwhile, this study suggests that PFO closure may be considered in older patients with cryptogenic embolism. However, the presence and number of cardiovascular risk factors favoring the atherothrombotic origin of cerebrovascular events should be taken into account in the clinical decision-making process in such patients. In addition, careful screening for arrhythmic events (particularly FA) should be undertaken in the workup before PFO closure.


J. Rodés-Cabau holds the Research Chair Fondation Famille Jacques Larivière for the Development of Structural Heart Disease Interventions. J. Wintzer-Wehekind was supported by a grant from the Association de Recherche Cardio-vasculaire des Alpes”. A. Alperi and D. del Val were supported by a grant from the Fundación Alfonso Martín Escudero, Madrid, Spain.


None declared.


  • Up to 4 recent randomized studies have established the superiority of PFO closure vs medical therapy for preventing recurrent ischemic events in patients younger than 60 years with cryptogenic stroke and PFO.

  • Even older patients with cryptogenic stroke exhibit a much higher prevalence of PFO compared with patients with stroke of known cause.

  • Mostly due to the lack of data, recent guidelines have excluded or failed to make strong recommendations for PFO closure in patients older than 60 years.


  • Among patients older than 60 years, closure of PFO was safe and associated with a low rate of stroke/TIA events.

  • Patients older than 60 years had a higher burden of cardiovascular risk factors, which could lead to a higher rate of ischemic cerebral recurrences.

  • Patients with cryptogenic stroke and patent foramen ovale should not be excluded from PFO closure simply because of their age.

J.-L. Mas, G. Derumeaux, B. Guillon, et al.
Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
N Engl J Med., 377 (2017), pp. 1011-1021
L. Søndergaard, S.E. Kasner, J.F. Rhodes, et al.
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
N Engl J Med., 377 (2017), pp. 1033-1042
P.H. Lee, J.-K. Song, J.S. Kim, et al.
Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial.
J Am Coll Cardiol., 71 (2018), pp. 2335-2342
J.L. Saver, J.D. Carroll, D.E. Thaler, et al.
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
N Engl J Med., 377 (2017), pp. 1022-1032
G. Turc, D. Calvet, P. Guérin, et al.
Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta-Analysis, and New Insights From the CLOSE Study.
J Am Heart Assoc., (2018), pp. 7
M.K. Mojadidi, A.Y. Elgendy, I.Y. Elgendy, et al.
Transcatheter Patent Foramen Ovale Closure After Cryptogenic Stroke: An Updated Meta-Analysis of Randomized Trials.
JACC Cardiovasc Interv., 10 (2017), pp. 2228-2230
C. Pristipino, H. Sievert, F. D’Ascenzo, et al.
European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism.
T. Kuijpers, F.A. Spencer, R.A.C. Siemieniuk, et al.
Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke?. A clinical practice guideline.
BMJ., 362 (2018), pp. k2515
J.-L. Mas, G. Chatellier.
Closure of patent foramen ovale in “cryptogenic” stroke: Has the story come to an end?.
Int J Stroke., 13 (2018), pp. 240-242
M. Handke, A. Harloff, M. Olschewski, A. Hetzel, A. Geibel.
Patent foramen ovale and cryptogenic stroke in older patients.
N Engl J Med., 357 (2007), pp. 2262-2268
M. Handke, A. Harloff, C. Bode, A. Geibel.
Patent foramen ovale and cryptogenic stroke: a matter of age?.
Semin Thromb Hemost., 35 (2009), pp. 505-514
N.W. Taggart, G.S. Reeder, R.J. Lennon, et al.
Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
Catheter Cardiovasc Interv., 89 (2017), pp. 124-133
F.M. Kiblawi, R.J. Sommer, S.G. Levchuck.
Transcatheter closure of patent foramen ovale in older adults.
Catheter Cardiovasc Interv., 68 (2006), pp. 136-142
C. Spies, A. Khandelwal, I. Timmemanns, C.J. Kavinsky, R. Schräder, Z.M. Hijazi.
Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism.
Catheter Cardiovasc Interv., 72 (2008), pp. 966-970
A. Wahl, T. Tai, F. Praz, et al.
Late results after percutaneous closure of patent foramen ovale for secondary prevention of paradoxical embolism using the amplatzer PFO occluder without intraprocedural echocardiography: effect of device size.
JACC Cardiovasc Interv., 2 (2009), pp. 116-123
P. Scacciatella, I. Meynet, P. Presbitero, et al.
Recurrent cerebral ischemia after patent foramen ovale percutaneous closure in older patients: A two-center registry study.
Catheter Cardiovasc Interv., 87 (2016), pp. 508-514
L. Cabanes, J. Coste, G. Derumeaux, et al.
Interobserver and intraobserver variability in detection of patent foramen ovale and atrial septal aneurysm with transesophageal echocardiography.
J Am Soc Echocardiogr., 15 (2002), pp. 441-446
H.P. Adams, B.H. Bendixen, L.J. Kappelle, et al.
Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
Stroke., 24 (1993), pp. 35-41
R. Mehran, S.V. Rao, D.L. Bhatt, et al.
Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.
Circulation., 123 (2011), pp. 2736-2747
D.M. Kent, R. Ruthazer, C. Weimar, et al.
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.
Neurology., 81 (2013), pp. 619-625
A.E. Merkler, G. Gialdini, S. Yaghi, et al.
Safety Outcomes After Percutaneous Transcatheter Closure of Patent Foramen Ovale.
Stroke., 48 (2017), pp. 3073-3077
Institut de la statistique du Québec (2018). Le bilan démographique du Québec. 2018. Available at: Accessed 25 Mar 2019.
D.S. Lee, M. Chiu, D.G. Manuel, et al.
Trends in risk factors for cardiovascular disease in Canada: temporal, socio-demographic and geographic factors.
CMAJ., 181 (2009), pp. E55-E66
A.A. Alsheikh-Ali, D.E. Thaler, D.M. Kent.
Patent foramen ovale in cryptogenic stroke: incidental or pathogenic?.
Stroke., 40 (2009), pp. 2349-2355
W.C. Choe, R.S. Passman, J. Brachmann, et al.
A Comparison of Atrial Fibrillation Monitoring Strategies After Cryptogenic Stroke (from the Cryptogenic Stroke and Underlying AF Trial).
Am J Cardiol., 116 (2015), pp. 889-893
Copyright © 2019. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

View newsletter history
Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?